Head and neck cancer immunotherapy: clinical evaluation

Area of Science:

• Oncology
• Immunology

Background:

• Head and neck squamous cell carcinoma (SCCHN) survival rates have stagnated despite decades of standard treatments.
• Novel therapeutic strategies are crucial for improving outcomes in SCCHN patients.

Purpose of the Study:

• To review current and developing immunotherapeutic strategies for SCCHN.
• To highlight the potential of immunotherapy in managing SCCHN.

Main Methods:

• Review of immunotherapeutic strategies in clinical trials and under development for SCCHN.
• Focus on antibody-based therapies targeting growth factor receptors.

Main Results:

• Immunotherapy shows potential for enhancing tumor lysis through immune activation.
• Current applications suggest immunotherapy is most effective after other interventions.
• Clinical evaluations indicate low toxicity associated with cancer immunotherapy.

Conclusions:

• Immunotherapy represents a significant advancement in SCCHN treatment.
• Further exploration of immunotherapy's clinical value is warranted.
• Novel immunotherapeutic approaches are vital for improving SCCHN patient survival.